BidaskClub Upgrades Wave Life Sciences (NASDAQ:WVE) to “Strong-Buy”

BidaskClub upgraded shares of Wave Life Sciences (NASDAQ:WVE) from a buy rating to a strong-buy rating in a research note released on Wednesday, December 4th, BidAskClub reports.

Other equities analysts have also recently issued reports about the company. Mizuho began coverage on Wave Life Sciences in a research report on Thursday, November 21st. They set a buy rating and a $65.00 price target on the stock. ValuEngine upgraded Wave Life Sciences from a buy rating to a strong-buy rating in a research report on Tuesday, October 29th. HC Wainwright set a $33.00 price target on Wave Life Sciences and gave the company a buy rating in a research report on Wednesday, October 9th. Zacks Investment Research lowered Wave Life Sciences from a buy rating to a hold rating in a research note on Saturday, October 19th. Finally, Guggenheim assumed coverage on Wave Life Sciences in a research note on Friday, November 1st. They set a buy rating and a $43.00 price objective for the company. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $37.50.

Shares of WVE stock traded down $0.33 during mid-day trading on Wednesday, hitting $15.81. 816,999 shares of the stock traded hands, compared to its average volume of 867,628. Wave Life Sciences has a twelve month low of $14.39 and a twelve month high of $48.64. The firm has a market cap of $553.27 million, a price-to-earnings ratio of -3.12 and a beta of 0.92. The company’s 50-day simple moving average is $27.83 and its 200-day simple moving average is $24.23. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.88 and a current ratio of 1.88.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.14). Wave Life Sciences had a negative net margin of 1,015.84% and a negative return on equity of 128.21%. The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $6.30 million. Analysts forecast that Wave Life Sciences will post -5.51 earnings per share for the current year.

In other news, VP Chandra Vargeese sold 6,000 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $32.34, for a total value of $194,040.00. Also, Director Gregory L. Verdine sold 30,039 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $30.63, for a total value of $920,094.57. Following the completion of the sale, the director now directly owns 36,009 shares of the company’s stock, valued at approximately $1,102,955.67. The disclosure for this sale can be found here. Company insiders own 39.70% of the company’s stock.

Several institutional investors have recently modified their holdings of WVE. Quantamental Technologies LLC acquired a new stake in shares of Wave Life Sciences in the second quarter worth $44,000. Aperio Group LLC acquired a new stake in shares of Wave Life Sciences in the second quarter worth $51,000. Bank of Montreal Can boosted its position in Wave Life Sciences by 590.5% during the second quarter. Bank of Montreal Can now owns 2,106 shares of the company’s stock valued at $55,000 after purchasing an additional 1,801 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Wave Life Sciences by 18.7% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,614 shares of the company’s stock valued at $94,000 after purchasing an additional 569 shares during the last quarter. Finally, Virtus ETF Advisers LLC boosted its position in Wave Life Sciences by 93.3% during the second quarter. Virtus ETF Advisers LLC now owns 10,387 shares of the company’s stock valued at $271,000 after purchasing an additional 5,014 shares during the last quarter. 90.00% of the stock is owned by institutional investors and hedge funds.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Read More: Dividend Aristocrat Index

Analyst Recommendations for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.